Cambridge Advisors Inc. Invests $222,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

by · The Markets Daily

Cambridge Advisors Inc. acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 2,650 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

Several other hedge funds have also made changes to their positions in GILD. Hennessy Advisors Inc. boosted its holdings in shares of Gilead Sciences by 0.7% during the first quarter. Hennessy Advisors Inc. now owns 61,100 shares of the biopharmaceutical company’s stock worth $4,476,000 after purchasing an additional 400 shares during the last quarter. Fifth Third Wealth Advisors LLC boosted its holdings in Gilead Sciences by 60.0% in the first quarter. Fifth Third Wealth Advisors LLC now owns 7,851 shares of the biopharmaceutical company’s stock valued at $575,000 after acquiring an additional 2,945 shares during the last quarter. Register Financial Advisors LLC boosted its holdings in Gilead Sciences by 6.4% in the first quarter. Register Financial Advisors LLC now owns 4,166 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 250 shares during the last quarter. Kathmere Capital Management LLC boosted its holdings in Gilead Sciences by 18.4% in the first quarter. Kathmere Capital Management LLC now owns 2,964 shares of the biopharmaceutical company’s stock valued at $217,000 after acquiring an additional 460 shares during the last quarter. Finally, Financial Management Professionals Inc. boosted its holdings in Gilead Sciences by 6.5% in the first quarter. Financial Management Professionals Inc. now owns 5,878 shares of the biopharmaceutical company’s stock valued at $431,000 after acquiring an additional 361 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,847 shares of company stock valued at $3,033,340. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of a number of research analyst reports. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price on the stock in a report on Monday, July 8th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Sanford C. Bernstein assumed coverage on Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective on the stock. Piper Sandler reissued an “overweight” rating and issued a $95.00 price objective on shares of Gilead Sciences in a research report on Wednesday, September 11th. Finally, Truist Financial raised their price objective on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Ten research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $86.85.

Read Our Latest Research Report on Gilead Sciences

Gilead Sciences Stock Up 1.8 %

Shares of Gilead Sciences stock opened at $88.78 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The firm has a market cap of $110.61 billion, a P/E ratio of 246.61, a P/E/G ratio of 2.98 and a beta of 0.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $89.21. The business has a 50-day moving average price of $81.87 and a 200 day moving average price of $73.17.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.47%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s payout ratio is 855.56%.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).